Holly Janes

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Also affiliated with University of Washington, Fred Hutch Cancer Center

MedicineImmunology and MicrobiologyMathematicsSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.215Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Descriptive, Hospital-Based, 10-Year Study of Malaria Transmission in Goa, a Southwest Indian State in the Malaria Elimination Phase

American Journal of Tropical Medicine and Hygiene(2024)10.4269/ajtmh.23-0828

Top 63%

0.215DataRank

Top 63%2 citations

Kevin Gillespie, Jayashri Walke, Mezia Fernandes, Anvily Almeida, Laura Chery-Karschney +13 more

Papers

Driven by 64 papers — median percentile 37. Top paper: “Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase”.

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

New England Journal of Medicine(2021)10.1056/nejmoa2113017

N/A

8.3DataRank · unranked

662 citations

Lindsey R. Baden, Brandon Essink, Susanne Doblecki‐Lewis, Judith M. Martin, Evan J. Anderson +33 more

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

Nature Communications(2023)10.1038/s41467-023-39292-w

N/A

1.9DataRank · unranked

44 citations

Meagan P. O’Brien, Jonathan Fintzi, Michael P. Fay, David C. Montefiori, Allyson Mateja +19 more

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

New England Journal of Medicine(2021)10.1056/nejmoa2035389

N/A

1.4DataRank · unranked

10600 citations

Hana M. El Sahly, Brandon Essink, Karen Kotloff, Sharon Frey, Rick Novak +32 more

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Science Translational Medicine(2023)10.1126/scitranslmed.ade9078

N/A

1.3DataRank · unranked

48 citations

David C. Montefiori, Adrian B. McDermott, Youyi Fong, Holly Janes, Weiping Deng +43 more

Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac260

N/A

1.1DataRank · unranked

50 citations

One Dintwe, Sheetal Sawant, Doug Grove, Yunda Huang, Holly Janes +43 more

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Journal of Clinical Investigation(2022)10.1172/jci160565

N/A

1.1DataRank · unranked

33 citations

Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck +18 more

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration

European Journal of Clinical Investigation(2011)10.1111/j.1365-2362.2011.02493.x

N/A

0.510DataRank · unranked

29 citations

John P. A. Ioannidis, Sara Bedrosian, Jonine L. Bernstein, Siobhan M. Dolan, Isabel Fortier +20 more

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

Open Forum Infectious Diseases(2024)10.1093/ofid/ofae689

N/A

0.444DataRank · unranked

8 citations

Xiaowei Wang, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Peter B. Gilbert +13 more

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Nature Communications(2024)10.1038/s41467-024-52348-9

N/A

0.428DataRank · unranked

9 citations

Youyi Fong, Jonathan Fintzi, Eric Chun‐Pu Chu, Holly Janes, Avi Kenny +37 more

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration

European Journal of Human Genetics(2011)10.1038/ejhg.2011.27

N/A

0.312DataRank · unranked

7 citations

Sara Bedrosian, Jonine L. Bernstein, Siobhan M. Dolan, Isabel Fortier, Andrew N. Freedman +21 more

Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns

medRxiv(2024)10.1101/2024.10.15.24315548

N/A

0.299DataRank · unranked

2 citations

Kennedy Otwombe, William O. Hahn, Shi‐Yu Chen, Deirdre Josipovic, Vuyelwa Baba +18 more

Descriptive, Hospital-Based, 10-Year Study of Malaria Transmission in Goa, a Southwest Indian State in the Malaria Elimination Phase

American Journal of Tropical Medicine and Hygiene(2024)10.4269/ajtmh.23-0828

Top 63%

0.215DataRank

Top 63%2 citations

Kevin Gillespie, Jayashri Walke, Mezia Fernandes, Anvily Almeida, Laura Chery-Karschney +13 more

Safety and implementation of phase I randomized GLA-SE–adjuvanted CH505TF gp120 HIV vaccine trial in newborns

Journal of Clinical Investigation(2025)10.1172/jci186927

N/A

0.208DataRank · unranked

3 citations

Kennedy Otwombe, William O. Hahn, Shi‐Yu Chen, Deirdre Josipovic, Vuyelwa Baba +18 more

Estimating vaccine efficacy during open-label follow-up of COVID-19 vaccine trials based on population-level surveillance data

Epidemics(2024)10.1016/j.epidem.2024.100768

N/A

0.104DataRank · unranked

1 citations

Yifan Zhu, Ian Hirsch, Tom White, Robert C. Reiner, Ryan M Barber +6 more

Discussion on “Estimating vaccine efficacy over time after a randomized study is unblinded” by Anastasios A. Tsiatis and Marie Davidian

Biometrics(2021)10.1111/biom.13542

N/A

0DataRank · unranked

1 citations

Fei Gao, Alex Luedtke, Holly Janes

Optimizing vaccine allocation for COVID-19 vaccines: potential role of single-dose vaccination

medRxiv(2021)10.1101/2020.12.31.20249099

N/A

0DataRank · unranked

36 citations

Julia Eaton, Tiffany Leung, Dobromir Dimitrov, Joshua T. Schiffer, David A. Swan +2 more

Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study

medRxiv(2021)10.1101/2021.11.10.21266139

N/A

0DataRank · unranked

7 citations

Elizabeth R. Brown, Myron S. Cohen, Dobromir Dimitrov, Holly Janes, Laura Matrajt

Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection

medRxiv(2021)10.1101/2021.04.16.21255614

N/A

0DataRank · unranked

2 citations

Yu Gu, Donglin Zeng, Holly Janes, Peter B. Gilbert, Dan-Yu Lin

Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition

medRxiv(2021)10.1101/2021.12.08.21267470

N/A

0DataRank · unranked

1 citations

Jessica E. Long, Aparajita Saha, Felicia K. Nguyen, Lara L. Joudeh, Ethan Valinetz +10 more

Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission

Viruses(2021)10.3390/v13101921

N/A

0DataRank · unranked

19 citations

Ashish Goyal, Chloe Bracis, Mia Moore, Elizabeth M. Krantz, Elizabeth R. Brown +10 more

Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Clinical Infectious Diseases(2021)10.1093/cid/ciab630

N/A

0DataRank · unranked

14 citations

Yu Gu, Donglin Zeng, Holly Janes, Peter B. Gilbert, Dan-Yu Lin

Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study

BMC Infectious Diseases(2022)10.1186/s12879-022-07639-1

N/A

0DataRank · unranked

29 citations

Elizabeth R. Brown, Myron S. Cohen, Dobromir Dimitrov, Holly Janes, Laura Matrajt

Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition

PLoS ONE(2022)10.1371/journal.pone.0267729

N/A

0DataRank · unranked

4 citations

Jessica E. Long, Aparajita Saha, Felicia K. Nguyen, Lara L. Joudeh, Ethan Valinetz +10 more

Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.15984

N/A

0DataRank · unranked

4 citations

Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Kathleen M. Neuzil, Lawrence Corey +7 more

Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial

medRxiv(2022)10.1101/2022.04.18.22271936

N/A

0DataRank · unranked

14 citations

Holly Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks +8 more

Estimating Counterfactual Placebo HIV Incidence in HIV Prevention Trials Without Placebo Arms Based on Markers of HIV Exposure

medRxiv(2022)10.1101/2022.05.06.22274780

N/A

0DataRank · unranked

3 citations

Fei Gao, David V. Glidden, Deborah Donnell, Holly Janes, Yifan Zhu

Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection

UNC Libraries(2022)10.17615/2a7e-y786

N/A

0DataRank · unranked

1 citations

Holly Janes, Peter B. Gilbert, Donglin Zeng, Yu Gu, Dan-Yu Lin

COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact

Scientific Reports(2021)10.1038/s41598-021-94719-y

N/A

0DataRank · unranked

100 citations

Chloe Bracis, Holly Janes, Mia Moore, Laura Matrajt, Daniel B. Reeves +6 more

Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination

Nature Communications(2021)10.1038/s41467-021-23761-1

N/A

0DataRank · unranked

162 citations

Julia Eaton, Tiffany Leung, Dobromir Dimitrov, Joshua T. Schiffer, David A. Swan +2 more

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

npj Vaccines(2023)10.1038/s41541-023-00630-0

N/A

0DataRank · unranked

40 citations

Youyi Fong, Holly Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule +37 more

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Viruses(2023)10.3390/v15102029

N/A

0DataRank · unranked

17 citations

Nima S. Hejazi, Bryan S. Blette, Lindsay N. Carpp, David Benkeser, David C. Montefiori +38 more

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial

International Journal of Infectious Diseases(2023)10.1016/j.ijid.2023.09.012

N/A

0DataRank · unranked

14 citations

Xiaoying Shen, Lindsay N. Carpp, David Benkeser, Dean Follmann, Holly Janes +8 more

Risk of COVID-19 after natural infection or vaccination

EBioMedicine(2023)10.1016/j.ebiom.2023.104799

N/A

0DataRank · unranked

13 citations

Matthew B. Laurens, Ying Huang, Chenchen Yu, Thomas Martin, Carina A. Rodriguez +94 more

Perspectives on Design Approaches for HIV Prevention Efficacy Trials

AIDS Research and Human Retroviruses(2023)10.1089/aid.2022.0150

N/A

0DataRank · unranked

11 citations

Roger Tatoud, Holly Janes, Stephaun E. Wallace, Veronica Miller, Linda‐Gail Bekker +2 more

Estimating counterfactual placebo HIV incidence in HIV prevention trials without placebo arms based on markers of HIV exposure

Clinical Trials(2023)10.1177/17407745231203327

N/A

0DataRank · unranked

10 citations

Fei Gao, David V. Glidden, Deborah Donnell, Holly Janes, Yifan Zhu

Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad069

N/A

0DataRank · unranked

10 citations

Holly Janes, Eric Chun‐Pu Chu, Lakshmi Jayashankar, Christos J. Petropoulos, Leonid Serebryannyy +19 more

Study design approaches for future active-controlled HIV prevention trials

Statistical Communications in Infectious Diseases(2023)10.1515/scid-2023-0002

N/A

0DataRank · unranked

7 citations

Sheila Kansiime, David V. Glidden, Alex Luedtke, Peter B. Gilbert, Fei Gao +2 more

Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2

American Journal of Epidemiology(2023)10.1093/aje/kwad046

N/A

0DataRank · unranked

5 citations

Fei Gao, Elizabeth R. Brown, Holly Janes, Marlena S. Bannick

Control groups for HIV prevention efficacy trials: what does the future hold?

Current Opinion in HIV and AIDS(2023)10.1097/coh.0000000000000818

N/A

0DataRank · unranked

4 citations

Susan Buchbinder, Holly Janes

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad500.2470

N/A

0DataRank · unranked

3 citations

Xiaowei Wang, Peter B. Gilbert, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink +10 more

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa

AIDS and Behavior(2023)10.1007/s10461-023-04025-z

N/A

0DataRank · unranked

3 citations

Fatima Laher, Athmanundh Dilraj, Philip Smith, Glenda Gray, Doug Grove +16 more

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

UNC Libraries(2023)10.17615/gg43-ax44

N/A

0DataRank · unranked

0 citations

David Benkeser, Baden L.R., Holly Janes, David C. Montefiori, Isa F. +19 more

COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact

UNC Libraries(2023)10.17615/4m4w-zr57

N/A

0DataRank · unranked

0 citations

Holly Janes, Daniel B. Reeves, Deborah Donnell, Joshua T. Schiffer, L. Matrajt +6 more

Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa

UNC Libraries(2023)10.17615/dzk5-b427

N/A

0DataRank · unranked

0 citations

Glenda Gray, Carl Lombard, Lindsay N. Carpp, Gita Ramjee, P.B. Gilbert +3 more

Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies

The Journal of Experimental Medicine(2024)10.1084/jem.20240604

N/A

0DataRank · unranked

29 citations

K. Rachael Parks, Mingchao Shen, Gabriel Ozorowski, Holly Janes, Lamar M. Fleming +32 more

Is HIV epidemic control by 2030 realistic?

The Lancet HIV(2024)10.1016/s2352-3018(24)00098-5

N/A

0DataRank · unranked

28 citations

Georgia D Tomaras, Huub C Gelderblom, Glenda E Gray, Holly Janes, Linda‐Gail Bekker +5 more

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

medRxiv(2020)10.1101/2020.12.14.20248137

N/A

0DataRank · unranked

25 citations

Jonathan Fintzi, Michael P. Fay, Holly Janes, Lindsey R. Baden, Hana M. El Sahly +25 more

Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities

Statistics in Biosciences(2020)10.1007/s12561-020-09292-1

N/A

0DataRank · unranked

5 citations

Yifan Zhu, Elizabeth R. Brown, Holly Janes

COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials

Clinical Infectious Diseases(2024)10.1093/cid/ciae192

N/A

0DataRank · unranked

6 citations

Jessica Tuan, Valeria D Cantos, Oladunni Adeyiga, Scott Mahoney, Ana M. Ortega‐Villa +25 more

The association of α4β7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies

EBioMedicine(2020)10.1016/j.ebiom.2020.103102

N/A

0DataRank · unranked

7 citations

Eshan U. Patel, Charles Kirby, Jacquie Astemborski, Gregory D. Kirk, Shruti H. Mehta +11 more

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature

Scientific Reports(2020)10.1038/s41598-020-69007-w

N/A

0DataRank · unranked

10 citations

Kelly E. Seaton, Michael S. Piepenbrink, John Hural, Paul Goepfert, Fatima Laher +11 more

Statistical design and analysis of controlled human malaria infection trials

Malaria Journal(2024)10.1186/s12936-024-04959-2

N/A

0DataRank · unranked

0 citations

Holly Janes, James G. Kublin, Xiaowen Tian

Incidence and prevalence of hepatitis C and B infections among men who have sex with men and transgender women enrolled in a United States HIV vaccine trial

Research Square(2024)10.21203/rs.3.rs-4474493/v1

N/A

0DataRank · unranked

0 citations

Vijay Nandi, Magdalena E. Sobieszczyk, Oliver Laeyendecker, Shelly Karuna, Michele P. Andrasik +4 more

Negative Control Outcome Adjustment in Early-Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants

arXiv (Cornell University)(2024)10.48550/arxiv.2410.08078

N/A

0DataRank · unranked

0 citations

Bo Zhang, Genevieve G. Fouda, Youyi Fong, Holly Janes, Ethan Ashby

Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration

UNC Libraries(2020)10.17615/6gxv-vj18

N/A

0DataRank · unranked

0 citations

John P. A. Ioannidis, Sara Bedrosian, Jonine L. Bernstein, Siobhan M. Dolan, Nicole F. Dowling +20 more

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo

Statistics in Medicine(2025)10.1002/sim.70022

N/A

0DataRank · unranked

2 citations

Holly Janes, Susan Buchbinder, Deborah Donnell, Fei Gao

Adopting the estimand framework in prophylactic vaccine trials

Vaccine(2025)10.1016/j.vaccine.2025.127645

N/A

0DataRank · unranked

1 citations

Naveen Karkada, Ye Yang, J. C. Scott, Lei Huang, Florian Klinglmüller +11 more

SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccines

Vaccine(2025)10.1016/j.vaccine.2025.127738

N/A

0DataRank · unranked

1 citations

Craig A. Magaret, Cindy Molitor, Leonid Serebryannyy, Sandeep Narpala, Mike Castro +7 more

Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to Adolescence

Current HIV Research(2025)10.2174/011570162x366522250721113420

N/A

0DataRank · unranked

1 citations

Anjali Singh, Ashley Nelson, Holly Janes, Troy Martin, Ofer Levy +7 more

Candidate Correlates of Protection in the HVTN505 HIV-1 Vaccine Efficacy Trial Identified by Positive-Unlabeled Learning

medRxiv(2025)10.1101/2025.09.03.25335025

N/A

0DataRank · unranked

0 citations

Aaron Hudson, Holly Janes, Georgia D Tomaras, Margaret E. Ackerman, Shujing Xu

Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study

PLOS Global Public Health(2025)10.1371/journal.pgph.0005156

N/A

0DataRank · unranked

0 citations

Shuying Sue Li, Jiani Hu, Samuel T. Robinson, Zaheer Hoosain, Nigel Garrett +16 more

Differences in neutralization susceptibility between clade C HIV viruses from breastmilk versus contemporaneous circulating viruses from sexually acquired infections

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.11.04.686466

N/A

0DataRank · unranked

0 citations

Kevin Gillespie, Elizabeth Domin, Genevieve G. Fouda, Sallie R. Permar, David C. Montefiori +2 more

Quantifying the Impact of Lifting Community Nonpharmaceutical Interventions for COVID-19 During Vaccination Rollout in the United States

Open Forum Infectious Diseases(2021)10.1093/ofid/ofab341

N/A

0DataRank · unranked

8 citations

Holly Janes, Joshua T. Schiffer, Dobromir Dimitrov, Laura Matrajt

A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples

The Journal of Infectious Diseases(2025)10.1093/infdis/jiaf572

N/A

0DataRank · unranked

0 citations

Lauren Dang, Eric Chun‐Pu Chu, Jonathan Fintzi, Holly Janes, Peter B. Gilbert +13 more

Holly Janes

Indexed papers

Top data-sharing exemplar

Papers